The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had …
Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »
The post Weekly reads: Sarepta, epigenomics, FDA on eyedrops appeared first on The Niche.